Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Istituto Nazionale Tumori Irccs - Fondazione G Pascale currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across distinct art units, indicating a specialized but multi-disciplinary approach to its medical research patenting. The presence of distinct examiners suggests that each pending matter is being handled by a different individual, which may lead to varied prosecution timelines and examination styles across the portfolio.
STEPHENS, AMELIA CAROLE is identified as the busiest examiner for this entity, currently overseeing 1 pending office action. Because this examiner holds 1 of the 3 total pending actions, the portfolio does not show a high concentration of risk or dependency on an examiner's discretion. Practitioners should prepare for individualized negotiations given that the workload is spread across the distinct examiners and distinct art units. This distribution requires a strategy that accounts for the specific tendencies of the art units involved in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17789398 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | JONES, DAMERON LEVEST | 5d |
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1627 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 17789398 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | JONES, DAMERON LEVEST | 1618 | §103 | Non-Final OA | 5d | Pending | Jun 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIstituto Nazionale Tumori Irccs - Fondazione G Pascale has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amelia Carole Stephens has the most, with 1 of Istituto Nazionale Tumori Irccs - Fondazione G Pascale's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
